Elisa M Ledet

List of Publications by Year
in descending order

33 papers	1,088 citations	686830 13 h-index	476904 29 g-index
33 all docs	33 docs citations	33 times ranked	1911 citing authors

#	Article	IF	Citations
1	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
2	Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart. Journal of Molecular Cell Biology, 2022, 14, .	1.5	0
3	The impact of genetic aberrations on response to radiumâ€223 treatment for castrationâ€resistant prostate cancer with bone metastases. Prostate, 2022, 82, 1202-1209.	1.2	4
4	Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. Prostate, 2021, 81, 427-432.	1.2	7
5	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate, 2021, 81, 433-439.	1.2	29
6	Letter to the Editor: â€œFamily history and pathogenic/likely pathogenic germline variants in prostate cancer patientsâ€• Prostate, 2021, 81, 1262-1263.	1.2	0
7	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate, 2021, 81, 1382-1389.	1.2	10
8	Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report. Clinical Genitourinary Cancer, 2020, 18, e312-e314.	0.9	6
9	TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 148-154.	0.9	7
10	Germline BLM mutations and metastatic prostate cancer. Prostate, 2020, 80, 235-237.	1.2	15
11	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100193.	0.7	2
12	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
13	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open, 2020, 3, e2021692.	2.8	70
14	Longâ€Term Disease Control Using Taxane/ Platinumâ€Based Chemotherapy in CDK12â€Mutated Advanced Prostate Cancer. Oncologist, 2020, 25, e1421-e1422.	1.9	3
15	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. Oncotarget, 2020, 11, 15-21.	0.8	9
16	Inherited DNA-repair gene mutations in African American men with prostate cancer. Oncotarget, 2020, 11, 440-442.	0.8	18
17	EPID-03. SINGLE INSTITUTIONAL CLINICAL AND GENETIC ANALYSIS OF METASTATIC PROSTATE CANCER WITH AND WITHOUT BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii78-ii79.	0.6	0
18	Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene, 2019, 38, 7060-7072.	2.6	31

#	Article	IF	Citations
19	High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 476-479.	0.9	1
20	Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC Cancer, 2019, 19, 524.	1.1	12
21	Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2019, 20, 100151.	0.7	5
22	Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncology, 2019, 5, 523.	3.4	240
23	Biomarkers for Programmed Deathâ€1 Inhibition in Prostate Cancer. Oncologist, 2019, 24, 444-448.	1.9	18
24	Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2018, 23, 791-797.	1.9	13
25	The association between germline <scp>BRCA2</scp> variants and sensitivity to platinumâ€based chemotherapy among men with metastatic prostate cancer. Cancer, 2017, 123, 3532-3539.	2.0	217
26	Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer. European Urology, 2017, 71, 997-998.	0.9	4
27	Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation. Clinical Genitourinary Cancer, 2017, 15, e69-e71.	0.9	28
28	Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient. Clinical Genitourinary Cancer, 2017, 15, e111-e113.	0.9	4
29	Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality. Clinical Genitourinary Cancer, 2016, 14, 139-148.	0.9	2
30	Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. Journal of Urology, 2016, 196, 1053-1060.	0.2	19
31	A Whole Blood Assay for AR-V7 and AR^{v567es}in Patients with Prostate Cancer. Journal of Urology, 2016, 196, 1758-1763.	0.2	46
32	Individualized Physical 3-dimensional Kidney Tumor Models Constructed From 3-dimensional Printers Result in Improved Trainee Anatomic Understanding. Urology, 2015, 85, 1257-1262.	0.5	79
33	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget, 2015, 6, 23358-23371.	0.8	79